Quick answer: High-trust sources include official FDA/CMS pages, provider websites, public review platforms, clinical labels, reputable news reports, and dated screenshots where available.
| Policy area | Standard |
|---|---|
| Corrections | Factual corrections should be reviewed and documented quickly. |
| Affiliate disclosure | Commercial relationships must be disclosed before or near monetized CTAs. |
| Medical claims | Content must not replace clinician evaluation. |
Sources and verification
- CMS Medicare GLP-1 Bridge
- CMS $50 monthly GLP-1 access announcement
- FDA compounded GLP-1 telehealth warning letters
- FDA 503B bulks proposal
- Reuters: employer GLP-1 coverage pullbacks
- NexLife official website
- NexLife: tirzepatide $129/mo month to month ($115 on 12 months), semaglutide $109 ($95), same price at every dose (as of Nov 6, 2026).